Enhancing Clinical Trials with Across Global Alliance and Wemedoo
Across Global Alliance Chooses Wemedoo's Oomnia for Clinical Trials
Across Global Alliance has made a significant decision by partnering with Wemedoo AG to implement oomnia, an advanced centralized clinical trial infrastructure. This move is set to bolster efficiency, enhance compliance, and foster better collaboration among its members who operate in over 90 countries worldwide.
A Transformative Approach to Clinical Trials
The decision to adopt oomnia comes after a comprehensive evaluation of various solutions. It became clear that oomnia was uniquely positioned to address the complex operational requirements of the alliance. By integrating multiple crucial clinical trial functions such as EDC (Electronic Data Capture), CTMS (Clinical Trial Management System), RTSM (Randomization and Trial Supply Management), and eTMF (Electronic Trial Master File) into one cohesive platform, oomnia effectively addresses inefficiencies that arise from the use of separate systems and disjointed data processes.
Seamless Collaboration and Enhanced Data Management
"Conducting global clinical trials necessitates a system that not only promotes seamless collaboration but also eliminates delays and ensures data consistency across all operational sites. With oomnia, we have discovered a platform that meets these urgent needs while ensuring compliance and offering operational flexibility," expressed Steven Bukvic, Chairman of Across Global Alliance.
Through its digital framework provided by oomnia, Across Global Alliance is dedicated to granting its clients and members access to a system that enhances clinical trial execution. This system supports real-time data quality reviews while maintaining user-friendly navigation.
The Vision Behind the Partnership
Nina Cihoric, CEO of Wemedoo AG, shared insights on the partnership, stating, "This collaboration with Across Global Alliance signifies another step towards transforming clinical trial management. By offering an integrated and adaptive system, we equip alliance members to concentrate on their scientific advancements rather than getting bogged down by administrative complexities."
About Across Global Alliance
Located in Singapore, Across Global Alliance is a strategic coalition of clinical research organizations (CROs) and specialist service providers that operate on a global scale. The alliance merges regional expertise with a common operational framework to offer a vast range of clinical research services across various therapeutic domains. This unified approach facilitates smooth coordination, ensures data integrity, and promotes operational excellence in the realm of global clinical research.
About Wemedoo
Wemedoo AG is a Swiss-based firm that excels in delivering healthcare data-driven solutions. By integrating groundbreaking technology with profound clinical knowledge, Wemedoo empowers research teams, CROs, and sponsors to conduct clinical trials with greater efficiency, minimize costs, and speed up the pace of medical innovation.
Frequently Asked Questions
What is the purpose of the partnership between Across Global Alliance and Wemedoo?
The partnership aims to implement oomnia as a centralized clinical trial infrastructure to enhance efficiency and collaboration among alliance members.
What features does oomnia provide?
Oomnia integrates key clinical trial functions such as EDC, CTMS, RTSM, and eTMF into one platform, which helps eliminate inefficiencies and data fragmentation.
How will this partnership impact clinical trial management?
This collaboration will streamline operations, reduce administrative burdens, and ensure compliance across multiple countries, thereby improving trial outcomes.
Who is Steven Bukvic?
Steven Bukvic is the Chairman of Across Global Alliance, and he emphasizes the importance of a seamless collaboration system for global clinical trials.
What does Wemedoo specialize in?
Wemedoo is focused on healthcare data-driven solutions, enabling more effective clinical trial management through advanced technological integration.
About The Author
Contact Henry Turner privately here. Or send an email with ATTN: Henry Turner as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
